Sarepta Therapeutics (AB3A) Financial Statements
Sarepta Therapeutics Financial Overview
Sarepta Therapeutics's market cap is currently $1.76B. The company's EPS TTM is $-1.44; its P/E ratio is -12.93; Sarepta Therapeutics is estimated to report earnings on November 5, 2026, and the estimated EPS forecast is $0.07. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 2.20B | $ 1.90B | $ 1.24B | $ 933.01M | $ 701.89M |
| Gross Profit | $ 1.32B | $ 1.58B | $ 1.09B | $ 793.02M | $ 604.84M |
| Operating Income | $ -657.77M | $ 218.08M | $ -267.82M | $ -536.20M | $ -459.71M |
| EBITDA | $ -647.97M | $ 316.89M | $ -453.69M | $ -594.85M | $ -317.41M |
| Net Income | $ -713.41M | $ 235.24M | $ -535.98M | $ -703.49M | $ -418.78M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 939.65M | $ 1.35B | $ 1.68B | $ 1.99B | $ 2.12B |
| Total Assets | $ 3.35B | $ 3.96B | $ 3.26B | $ 3.13B | $ 3.15B |
| Total Debt | $ 1.04B | $ 1.34B | $ 1.40B | $ 1.62B | $ 1.15B |
| Net Debt | $ 238.46M | $ 240.06M | $ 968.38M | $ 650.58M | $ -962.43M |
| Total Liabilities | $ 2.21B | $ 2.44B | $ 2.41B | $ 2.74B | $ 2.22B |
| Stockholders' Equity | $ 1.14B | $ 1.53B | $ 859.34M | $ 384.95M | $ 928.01M |
| Cash Flow | |||||
| Free Cash Flow | $ -307.45M | $ -352.74M | $ -588.34M | $ -357.60M | $ -481.66M |
| Operating Cash Flow | $ -205.48M | $ -205.79M | $ -500.99M | $ -325.35M | $ -443.17M |
| Investing Cash Flow | $ 69.64M | $ 755.56M | $ -165.80M | $ -1.05B | $ 495.41M |
| Financing Cash Flow | $ -168.34M | $ 124.81M | $ 125.00M | $ 232.51M | $ 561.57M |
Currency in USD
